Abecma denied as experimental or investigational by Humana?

Humana's specific coverage criteria for abecma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Abecma as Experimental

Abecma (idecabtagene vicleucel) received FDA approval for relapsed or refractory multiple myeloma. Despite this, Humana may issue an "experimental or investigational" denial when a patient's specific disease characteristics — such as the number of prior lines of therapy, prior stem cell transplant history, or organ function parameters — fall outside the exact population described in Humana's current coverage criteria for Abecma. The denial does not necessarily mean Humana disputes CAR-T therapy in general; it typically means that Humana's clinical reviewer concluded this particular patient does not match the covered indication as Humana has defined it.

## Why FDA Approval Matters — and Its Limits in Appeals

FDA approval establishes that a drug is safe and effective for its labeled indication. However, insurer coverage policies sometimes define the covered population more narrowly than the FDA label, or require documentation of criteria the label does not explicitly mandate. In an appeal, you need to demonstrate not just that Abecma is FDA-approved, but that this patient meets Humana's specific published criteria. Obtain and read Humana's current medical policy for Abecma before drafting the appeal.

## Federal Appeal Rights

ACA Section 2719 entitles you to free external review by an Independent Review Organization once Humana's internal appeals are exhausted. ERISA Section 503 governs self-funded employer plans. The external-review window is approximately four months from the final internal denial date. Given the acute nature of relapsed/refractory myeloma, file for expedited internal and external review immediately — do not wait for standard timelines.

## Documentation to Gather

• Treating oncologist's medical-necessity letter: Should directly address each criterion in Humana's published coverage policy for Abecma, citing specific chart findings that demonstrate the patient meets the covered indication. The letter should also reference the applicable NCCN guideline organization's categorization of Abecma for this patient's situation.
• Complete prior-therapy history: A line-by-line list of every prior myeloma regimen, including agent names, dates, responses, and reasons for discontinuation — documenting that the patient has received the required prior lines of therapy per the FDA-approved prescribing label and Humana's policy.
• Disease status documentation: Recent bone marrow biopsy, serum protein electrophoresis, and imaging confirming current relapsed or refractory status — consult the FDA-approved prescribing label for the specific parameters required.
• Eligibility confirmation: Document that the patient meets every eligibility parameter stated in Humana's coverage policy and the FDA label — obtain those exact thresholds from those two primary sources rather than any secondary summary.
• Humana's current coverage policy: Download the version in effect at the time of denial and map every criterion to a chart document.

## Appeal Structure

1. Read the denial letter and identify the exact experimental-criteria language used. 2. Build a criteria map: each Humana policy requirement → specific chart evidence. 3. Have the treating oncologist co-sign the appeal letter with explicit criterion-by-criterion responses. 4. Cite FDA approval and the applicable NCCN guideline category. 5. File for expedited external review immediately after internal denial, given disease urgency.